Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.63B P/E - EPS this Y -6.30% Ern Qtrly Grth -
Income -219.55M Forward P/E -10.32 EPS next Y 58.80% 50D Avg Chg -
Sales 1.37M PEG -2.61 EPS past 5Y - 200D Avg Chg 18.00%
Dividend N/A Price/Book 4.99 EPS next 5Y 5.00% 52W High Chg -17.00%
Recommedations 1.60 Quick Ratio 3.53 Shares Outstanding 602.80M 52W Low Chg 64.00%
Insider Own 0.09% ROA -32.87% Shares Float 555.88M Beta 0.51
Inst Own 77.97% ROE -72.56% Shares Shorted/Prior 71.51M/69.11M Price 3.20
Gross Margin - Profit Margin - Avg. Volume 5,610,301 Target Price 7.31
Oper. Margin -7,860.88% Earnings Date Oct 31 Volume 2,355,788 Change -0.31%
About Geron Corporation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation News
11/11/24 Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
11/11/24 Geron to Participate in the Stifel 2024 Healthcare Conference
11/10/24 Analysts Are Upgrading Geron Corporation (NASDAQ:GERN) After Its Latest Results
11/09/24 Geron Third Quarter 2024 Earnings: Beats Expectations
11/08/24 Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ...
11/08/24 Geron Secures $250M Funding and Strong Q3 Sales
11/08/24 Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
11/07/24 Geron (GERN) Q3 2024 Earnings Call Transcript
11/07/24 Geron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors
11/07/24 Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
11/07/24 Geron: Q3 Earnings Snapshot
11/07/24 Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
11/07/24 Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
11/07/24 Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/05/24 Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
10/17/24 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/16/24 Is Geron Corporation (GERN) the Hottest Penny Stock to Invest in According to Hedge Funds?
10/15/24 Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
10/12/24 Is Geron Corporation (GERN) the Best Growth Stock Under $10 to Buy?
10/10/24 Is Geron Corporation (GERN) the Best Stock Under $10 With High Potential?
GERN Chatroom

User Image Winning_calls Posted - 4 hours ago

$GERN pick me up @ $4.02♤♤

User Image Copperdust Posted - 8 hours ago

$GERN Geron Corporation (NASDAQ: GERN) is poised for a significant breakout following the ASH 2024 conference (Dec 7-9), where it will showcase pivotal data on its groundbreaking telomerase inhibitor, imetelstat. With strong Phase III results in lower-risk MDS, a clear path to regulatory approval, and an estimated multibillion-dollar market opportunity, Geron stands out as a biotech underdog ready to soar. ASH offers a platform to attract institutional interest, potential partnerships, and broader recognition of its value, making it a compelling stock to watch as the event unfolds.

User Image BioRich Posted - 13 hours ago

$VRNA let's slap that 40! Fun watching this one and $TGTX. They seem to track ups and downs together. They remind me of $GERN with $CRMD. No technical basis or reason for comparison other than they simply remind me of each other. Either way, best of luck. Cheers!

User Image TMXAnGeL Posted - 14 hours ago

$GERN Can’t hold $4.. pussies. Getting close to the end of the day MUST MAKE PENNIES.. pathetic.

User Image Huntlardo Posted - 15 hours ago

$GERN as I said, there was a pretty clear, inverse head and shoulders, forming on the one year chart

User Image patso1964 Posted - 16 hours ago

$GERN go baby give us a 4$

User Image Copperdust Posted - 16 hours ago

$GERN shorts are trapped! 76 million of them.

User Image BioRich Posted - 1 day ago

$GERN let's get this through 4 for good. A little ways to go, but I think we'll flow through and not look back. It's time.

User Image patso1964 Posted - 1 day ago

$GERN yes 2180 share @ 3.69

User Image Mail_Dog Posted - 1 day ago

$GERN Co. appears to be on the right track for growth - stock peformance though just down outright pathetic…

User Image Huntlardo Posted - 1 day ago

$GERN The stifle analyst also believes there is a big delta in analysts revenue modeling that is being left out and that’s the patients that will inevitably stay on drug even if they don’t achieve the TI targets becuase the transfusion burden is dropped because of the drugs inherent effects on the cancer

User Image TickerDD_com Posted - 1 day ago

How much is $GERN Shorted? What is Short Interest for GERN? As of October 31 2024 Settlement Date https://youtu.be/kBtkWMgefLg

User Image ZoeyTanner Posted - 1 day ago

$GERN NO excitement with geron only waiting for other shoe to drop anything to move up not down everyday down

User Image Huntlardo Posted - 1 day ago

$GERN inverse head and shoulders pattern forming, top of the head was at the first time the chart hit oversold on the yearly chart.

User Image Longwoodjones Posted - 1 day ago

$GERN could this be the start of a gradual climb back up?

User Image MR2601 Posted - 2 days ago

$GERN is way cheap at this level. Once the sales gets traction which we can feel from the last qtr ; the SP shall appreciate significantly. BO is also in the horizon. Minimum risk but reward seems to be great.

User Image TMXAnGeL Posted - 2 days ago

$GERN can’t hold 3.85.. always has to drop at the end for penny scalpers. Eat shit

User Image Huntlardo Posted - 2 days ago

$GERN nice conference with stifel, 3-4 quarters of revenue before issuing guidance. VP of R&D is for all of the above; pipeline expansion, indication expansion, Ip expansion and so on. Expecting second and third line patients to stay on drug for other benefits outside of transfusion dependence.

User Image 1Darrell1965 Posted - 2 days ago

$GERN I submitted a question to EMA regarding Imet and Oct meeting. Their response is below. Dear Mr ###%%^, thank you for question regarding imetelstat. As you've mentioned, this was product was included in the Agenda for the October CHMP meeting but not in the highlights of the same meeting. Highlights of the CHMP meeting refer to procedures which have concluded, with either positive or negative outcome. If you have a look at the Agenda again, you will see that the procedure for imetelsatat was included in order to adopt the " List of outstanding issues" by the CHMP. What this means is that the Committee has now agreed on a new list of questions that will need to be addressed by the applicant before an Opinion on this application can be adopted. I trust this addresses your query.

User Image Rickster4retirement Posted - 2 days ago

$GERN All the Trump pumpers ID biotech and pharma. We'll, where's your messiah now?

User Image share97 Posted - 4 days ago

$GERN RFK is trying to MAHA not make America more broke.

User Image BubblesMcGee123 Posted - 5 days ago

$GERN "There was no vaccine for the Spanish flu. Pharmaceutical companies were working to develop a vaccine, but the virus disappeared before they could isolate it. The Spanish flu, also known as the 1918 influenza pandemic, killed more than 50 million people worldwide."

User Image BubblesMcGee123 Posted - 5 days ago

$GERN Just one of many articles on Kennedy's nomination's impact on pharma: https://www.nytimes.com/2024/11/15/business/dealbook/trump-robert-f-kennedy-stocks.html?smid=nytcore-android-share

User Image DAWGNuts Posted - 5 days ago

$GERN pretty sure Baker Bros want back in and for a better price. I'm buying more at $3.25

User Image LoveRetailFroth Posted - 5 days ago

$VNDA $18. $GERN $8 🥪

User Image mmatisse Posted - 5 days ago

$GERN Good results for Gern daughter $ LCTX

User Image Fern64 Posted - 5 days ago

$GERN https://www.tandfonline.com/doi/full/10.1080/10428194.2024.2426057

User Image BubblesMcGee123 Posted - 5 days ago

$GERN Hopefully the senate won't confirm RFK Jr.'s nomination. It's not just his stance on vaccines that's crazy but also his views on cell phones, pesticides, and ultrasound causing peanut allergies and Tourettes. He is a conspiracy theorist when it comes to disease.

User Image Longwoodjones Posted - 5 days ago

$GERN where's the bottom? Who sells at these prices? The stock is on sale, people should be buying it up, it's 50% off, it's buy one get one free

User Image BubblesMcGee123 Posted - 5 days ago

$GERN RFK's nomination is causing this downward spiral in biotech indexes and biotech and Big Pharma stocks. His stance on vaccines and general ignorance are contrary to modern science. Big Pharma is the one who's supposed to buy Geron, and now it looks like they'll have less money in their own coffers. Obviously, this drop is just an (over)-reaction. We will see. Kennedy got into trouble with the World Health Organization(WHO) regarding vaccines -- it concerned another country, not the USA -- though I can't recall the name of that country. He then denied that he was against vaccines.

Analyst Ratings
Leerink Partners Outperform Sep 9, 24
Needham Buy Aug 9, 24
Needham Buy Jul 26, 24
Barclays Overweight Jun 11, 24
Barclays Overweight Jun 10, 24
Stifel Buy Jun 10, 24
Needham Buy Jun 7, 24
Wedbush Outperform Jun 7, 24
Needham Buy May 2, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
O'Farrell Elizabeth G. Director Director Aug 24 Buy 2.28 13,186 30,064 26,220 08/24/23
LAWLIS V BRYAN Director Director May 11 Sell 3 35,000 105,000 05/11/23
LAWLIS V BRYAN Director Director May 11 Option 1.1 35,000 38,500 35,000 05/11/23
Molineaux Susan Director Director May 01 Sell 2.48 35,000 86,800 05/01/23
Molineaux Susan Director Director May 01 Option 1.1 35,000 38,500 35,000 05/01/23
GRETHLEIN ANDREW J EVP, Chief Operating.. EVP, Chief Operating Officer Feb 09 Sell 3.03 384,719 1,165,699 02/10/23
GRETHLEIN ANDREW J EVP, Chief Operating.. EVP, Chief Operating Officer Feb 09 Option 1.51 150,000 226,500 384,719 02/10/23
Bloom Olivia Kyusuk EVP, Chief Financial.. EVP, Chief Financial Officer Feb 08 Sell 3.08 400,000 1,232,000 74,588 02/10/23
Bloom Olivia Kyusuk EVP, Chief Financial.. EVP, Chief Financial Officer Feb 08 Option 1.51 400,000 604,000 474,588 02/10/23
SCARLETT JOHN A Chairman, President.. Chairman, President and CEO Feb 08 Sell 3.04 1,340,000 4,073,600 02/10/23
SCARLETT JOHN A Chairman, President.. Chairman, President and CEO Feb 08 Option 1.5 1,340,000 2,010,000 446,668 02/10/23
EASTHAM KARIN Director Director Jan 13 Option 1.10 35,000 38,500 109,047 01/17/23
GRETHLEIN ANDREW J EVP, Chief Operating.. EVP, Chief Operating Officer Sep 12 Option 1.7 234,719 399,022 234,719 09/14/22
EASTHAM KARIN Director Director Apr 20 Option 1.41 35,000 49,350 74,047 04/21/22